Edition:
United States

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.39USD
4:00pm EDT
Change (% chg)

$-0.02 (-4.48%)
Prev Close
$0.41
Open
$0.42
Day's High
$0.42
Day's Low
$0.37
Volume
76,542
Avg. Vol
110,636
52-wk High
$2.13
52-wk Low
$0.28

Chart for

About

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused... (more)
No analyst recommendations are available for .

Overall

Beta: 2.46
Market Cap(Mil.): €11.91
Shares Outstanding(Mil.): 34.72
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.51 16.34
EPS (TTM): -- -- --
ROI: -- 13.78 14.66
ROE: -- 16.61 14.00

BRIEF-Cytori Therapeutics enters into an amendment to its existing loan and security agreement

* Cytori Therapeutics- On September 20, 2017, co entered into an amendment to its existing loan and security agreement, dated May 29, 2015 - SEC filing

Sep 21 2017

BRIEF-Cytori announces corporate restructuring & cost reduction plan

* Cytori announces corporate restructuring & cost reduction plan

Sep 01 2017

BRIEF-Cytori Therapeutics Q2 loss per share $0.19

* Cytori reports second quarter 2017 business and financial results

Aug 10 2017

BRIEF-Cytori announces top-line 24- and 48-week results

* Cytori announces top-line 24- and 48-week results from the star trial of habeo cell therapy in patients with scleroderma

Jul 24 2017

BRIEF-AMA approves new category III CPT codes describing Cytori’S Scleroderma therapy

* American Medical Association approves new category III CPT codes describing Cytori’S Scleroderma therapy Source text for Eikon: Further company coverage:

Jul 10 2017

BRIEF-Cytori Therapeutics receives key cell therapy patent for scleroderma

* Cytori Therapeutics - receives key cell therapy patent for scleroderma, patent has a term at least through 2034 Source text for Eikon: Further company coverage:

Jul 06 2017

BRIEF-Cytori Therapeutics announces publication of long-term follow-up data for cancer recurrences following use of Cytori cell therapy

* Cytori Therapeutics announces publication of long-term follow-up data for cancer recurrences following use of Cytori cell therapy

Jun 08 2017

BRIEF-Cytori Therapeutics announces plans to introduce next-gen Celution technology

* Announces plans to introduce its next-generation Celution technology

Jun 01 2017

BRIEF-Cytori and Barda execute $13.4 mln contract option for burn clinical trial

* Cytori and Barda execute $13.4 million contract option for burn clinical trial

May 31 2017

BRIEF-Cytori and Barda execute $13.4 mln contract option for burn clinical trial

* Cytori and Barda execute $13.4 million contract option for burn clinical trial

May 31 2017

Earnings vs. Estimates